Join the IMF Patient & Family Webinar. This free two-hour webinar features a panel discussion about the latest treatments, diversity and caregiver support led by IMF Chief Medical Officer Dr. Joseph Mikhael of Translational Genomics Research Institute (TGen). IMF President, Founder, and CEO Susie Durie and IMF Vice President of Support Groups Robin Tuohy will lead a special segment dedicated to caregiver support.

Other panelists include Deepu Madduri, MD of Tisch Cancer Institute/Mount Sinai Hospital; Craig Emmitt Cole, MD of Michigan State University; and Beth Faiman PhD, MSN, APRN-BC, AOCN, FAAN of Cleveland Clinic Taussig Cancer Institute.

6th World Congresses on Controversies in Multiple Myeloma (COMy)

This meeting will bring together leading experts in multiple myeloma who will discuss the use of measurable residual disease (MRD) in clinical and trial settings, furthering our understanding of recent advances in the disease, and encouraging interactive discussions.

Despite expanding treatment options for relapsed/refractory multiple myeloma (MM), hematology/oncology teams face persistent barriers to the delivery of quality care across MM patient populations. Join our expert faculty for this live webinar as they share real-world insights and lessons learned from an MM quality initiative conducted within two large oncology health systems.

The North America IMS Educational Workshop scheduled to occur in Miami, Florida will now be offered in a virtual format on November 6-7, 2020. While advance registration is required, access to the above IMS Educational Workshops will be made available on a complimentary basis for all IMS members. The registration rate for non-members will be […]

In this live webcast, expert faculty will discuss the best practices in treating patients with relapsed/refractory multiple myeloma and discuss the patient's perspective on treatment options.Learners will also get a look ahead at emerging therapeutic strategies and clinical trials that may soon change practice.

Within a very short period of time, there has been a tremendous advance in development of cellular immunotherapies in multiple myeloma (MM). As we have observed during our event last year, a number of groups have presented their data on CAR T-cell therapy in MM. Although the studies are currently small in size, they are accruing patients very quickly, both in the United States and globally.

These developments have highlighted the need for a focused discussion about the state-of-the-art in immune and cellular therapies. With this in mind, the International Myeloma Society (IMS) is organizing the 2nd Immune Effector Cell Therapy in Multiple Myeloma Workshop. This two-day meeting will review CAR-T clinical data and promising preclinical leads, gain consensus on issues in management of toxicity, and discuss ongoing and future clinical trials. This year we are also including a session on T cell-engaging bispecific antibody-based approaches.

                        The International Myeloma Workshop is the defining meeting in myeloma with a focus on both the basic, preclinical and the clinical aspects, including: Scientific Programs Oral Presentations (on Basic Biology, Preclinical Trials and Clinical Studies) Consensus Panels Poster Presentations

Join us in Athens, Greece from September 27-30, 2023 for the 20th International Myeloma Society Annual Meeting and Exposition! Image by George E. Koronaios - CC BY-SA 4.0

The 65th ASH Annual Meeting and Exposition will take place December 9-12, 2023, in San Diego, California, and online. Mark your calendars now to attend the world’s most comprehensive hematology event of the year.